Ovagen
Ovarian Bioregulator
Not medical advice. Educational reference only.
- Route
- Subcutaneous injection (preparation guidance); protocol routes vary
- Storage
- Keep refrigerated at 2–8°C and use within 28 days.
What is Ovagen?
Ovagen is an investigational peptide bioregulator studied in relation to ovarian function and endocrine signaling. It has no FDA approval, and its proposed hormonal applications remain research topics.
Research indications
Hormonal Regulation
Most effectiveEndocrine activity is a principal research focus, with direct effects on hormonal signaling.
Reproductive Health
EffectiveFertility and reproductive medicine are areas of investigation and clinical interest.
Metabolic Support
ModerateHormonal signaling may produce secondary effects on metabolic function.
Interactions
Medications
CautionConsult your prescriber before combining this compound with any medication.
BPC-157
CompatibleNAD+
CompatibleVitamin D
Compatible
How to reconstitute and inject
Diluent: Use bacteriostatic water; avoid saline because it may cause precipitation.
- Let your refrigerated Ovagen vial warm to room temperature for 15–20 minutes before preparation.
- Disinfect the vial’s rubber closure with an alcohol wipe, then wait until it has dried completely.
- Use a sterile syringe to measure the calculated amount of bacteriostatic water. Avoid saline because precipitation may occur.
- Add the water slowly against the vial’s inner wall. Keep the stream away from the dry powder itself.
- Rotate the vial gently to mix its contents. Do not shake forcefully, because this can damage the peptide.
- Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is transparent and has no color.
- Measure your calculated subcutaneous dose with an insulin syringe after dissolution.
- Choose the abdomen, upper arm or thigh for injection. Alternate the injection location each time to help prevent lipodystrophy.
- Refrigerate the mixed solution at 2–8°C, and discard any remainder after 28 days. Use these steps only for an appropriate research formulation; follow the specific product instructions for prescription presentations.
What to expect
- Week 1–2
- An early adjustment period may accompany initial effects. Watch for adverse reactions while assessing tolerance.
- Week 2–4
- The main effects may begin to emerge. Change the dose only in accordance with your clinician’s recommendations.
- Week 4–8
- The intended effects may become established during this interval. Review your progress together with your clinician.
- Week 8+
- Reassess the outcome and discuss whether to continue, introduce a cycle break or change the dose. These research expectations do not establish individual treatment outcomes.
Side effects and safety
- Local redness, bruising or mild pain after an injection
- Possible allergic reactions, including rash or hives; stop use if these develop
Ovagen: not approved in the US.
Regulatory status
US
Not approvedFDA — No US approval. Research use does not constitute approval for treatment in humans.
- Rx required
- No
- Telehealth
- N/A
Frequently asked questions
Which dosing approaches are discussed?
The starting research approach uses a low dose, followed by titration for the standard approach. Neither approach defines a numeric amount. Frequency depends on the particular protocol, and the route varies; these descriptions therefore do not establish a dosing regimen. Discuss any use with a qualified clinician rather than selecting an amount from these qualitative terms.
What should you know about unwanted effects?
Adverse effects can differ according to dose, administration route and individual response. Begin only at the lowest clinician-directed amount and monitor your response carefully. Seek advice before use, and report any unusual symptoms to your healthcare professional. Human safety is not fully characterized for experimental applications.
References
Peptide bioregulators and liver function in aging models (2012)
Peptide bioregulation of aging: results and prospects. (2010)